TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: School Wellness Policy: RCT to Implement & Evaluate Impact on Childhood Obesity
Brief Summary: Our long-term objective is to reduce the rates and risk of childhood obesity via school-based nutrition and physical activity policies. Using a randomized design, we propose to monitor and evaluate how Connecticut's first-ranked District Wellness Policy, in the New Haven Public School district, is implemented and determine its impact on children's obesogenic behaviors, weight outcomes, and school performance. This study is designed to significantly advance empirical research on school wellness policies and to provide important evidence to guide future interventions in schools and communities - translating science to improved health of the public.


Options:
A: Arm Label: Bicycle Train Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Bicycle Train | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Bicycle Train; Assigned to Arm(s): Bicycle Train Intervention
B: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: lifestyle counseling | Intervention Type: BEHAVIORAL; Name: lifestyle counseling; Assigned to Arm(s): lifestyle counseling
C: Arm Label: Internet-supported FeetEnergy approach; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-supported FeetEnergy approach | Arm Label: Usual health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual health education | Intervention Type: BEHAVIORAL; Name: Internet-supported FeetEnergy approach; Assigned to Arm(s): Internet-supported FeetEnergy approach | Intervention Type: BEHAVIORAL; Name: Usual health education; Assigned to Arm(s): Usual health education
D: Arm Label: Physical Activity Only; Type: EXPERIMENTAL; Interventions: Other: OPPORTUNITIES FOR PHYSICAL ACTIVITY | Arm Label: Delayed Interventions Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutrition and Physical Activity; Type: EXPERIMENTAL; Interventions: Other: DISTRICT WELLNESS COMMITTEE, Other: NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS, Other: HEALTH PROMOTION AND MARKETING, Other: OPPORTUNITIES FOR PHYSICAL ACTIVITY | Arm Label: Nutrition Only Interventions; Type: EXPERIMENTAL; Interventions: Other: NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS | Intervention Type: OTHER; Name: DISTRICT WELLNESS COMMITTEE; Assigned to Arm(s): Nutrition and Physical Activity | Intervention Type: OTHER; Name: NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS; Assigned to Arm(s): Nutrition Only Interventions, Nutrition and Physical Activity | Intervention Type: OTHER; Name: HEALTH PROMOTION AND MARKETING; Assigned to Arm(s): Nutrition and Physical Activity | Intervention Type: OTHER; Name: OPPORTUNITIES FOR PHYSICAL ACTIVITY; Assigned to Arm(s): Nutrition and Physical Activity, Physical Activity Only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Intravenous Acetaminophen on Post-operative Pain and Narcotic Consumption in Vaginal Reconstructive Surgery Patients: A Randomized Controlled Trial
Brief Summary: This randomized controlled trial will evaluate the effects of perioperative intravenous (IV) acetaminophen on postoperative narcotic consumption and pain scores in subjects undergoing vaginal reconstructive surgery. One hundred subjects will be randomly assigned to receive either IV acetaminophen or IV placebo. Those in the IV acetaminophen group will receive 1000mg IV every 6 hours for 24 hours beginning prior to anesthesia induction. The control group will receive placebo saline infusions at the same time intervals. All subjects will receive as needed (prn) IV narcotic for additional pain relief. Visual analog scales (VAS) regarding pain will be evaluated at 18 and 24 hours postoperative and immediately prior to discharge. We will also collect total IV narcotic consumption. We hypothesize that subjects receiving IV acetaminophen will have lower VAS scores and decreased total narcotic consumption in comparison to the control group.


Options:
A: Arm Label: IV Acetaminophen; Type: EXPERIMENTAL; Interventions: Drug: IV Acetaminophen | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Acetaminophen | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen, Saline
B: Arm Label: SSLF and PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF, Behavioral: PMT | Arm Label: ULS and PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS, Behavioral: PMT | Arm Label: SSLF without PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF | Arm Label: ULS without PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS | Intervention Type: PROCEDURE; Name: SSLF; Assigned to Arm(s): SSLF and PMT, SSLF without PMT | Intervention Type: PROCEDURE; Name: ULS; Assigned to Arm(s): ULS and PMT, ULS without PMT | Intervention Type: BEHAVIORAL; Name: PMT; Assigned to Arm(s): SSLF and PMT, ULS and PMT
C: Arm Label: Nitrofurantoin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Nitrofurantoin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: No dilator use; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dilator use; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dilator use | Intervention Type: BEHAVIORAL; Name: Dilator use; Assigned to Arm(s): Dilator use

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The ProtecT Trial - Evaluating the Effectiveness of Treatments for Clinically Localised Prostate Cancer
Brief Summary: RATIONALE: Radical prostatectomy is surgery to remove the entire prostate. Radiation therapy uses high-energy x-rays or other types of radiation to kill tumor cells. Sometimes the tumor may not need treatment until it progresses. In this case, active surveillance may be sufficient. It is not yet known which treatment regimen is more effective for localized prostate cancer.

PURPOSE: This randomized phase III trial is studying active monitoring to see how well it works compared with radical prostatectomy or radiation therapy in treating patients with localized prostate cancer.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy 70 Gy, Drug: Androgen blockade | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy 76 Gy, Drug: Androgen blockade | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy 76 Gy | Intervention Type: RADIATION; Name: Radiotherapy 70 Gy; Assigned to Arm(s): Arm 1 | Intervention Type: RADIATION; Name: Radiotherapy 76 Gy; Assigned to Arm(s): Arm 2, Arm 3 | Intervention Type: DRUG; Name: Androgen blockade; Assigned to Arm(s): Arm 1, Arm 2
B: Arm Label: Conventional 3D-CRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conventional 3D-CRT or IMRT | Arm Label: Hypofractionated 3D-CRT; Type: EXPERIMENTAL; Interventions: Radiation: Hypofractionated 3D-CRT or IMRT | Intervention Type: RADIATION; Name: Conventional 3D-CRT or IMRT; Assigned to Arm(s): Conventional 3D-CRT | Intervention Type: RADIATION; Name: Hypofractionated 3D-CRT or IMRT; Assigned to Arm(s): Hypofractionated 3D-CRT
C: Arm Label: Radical prostatectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radical prostatectomy | Arm Label: Conformal radiation therapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conformal radiation therapy | Arm Label: Active monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Active monitoring | Intervention Type: PROCEDURE; Name: Radical prostatectomy; Assigned to Arm(s): Radical prostatectomy | Intervention Type: RADIATION; Name: Conformal radiation therapy; Assigned to Arm(s): Conformal radiation therapy | Intervention Type: OTHER; Name: Active monitoring; Assigned to Arm(s): Active monitoring
D: Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel-group Phase 2 Dose Selection Study of Lorcaserin Hydrochloride, an Oral 5-HT2C Receptor Agonist for Smoking Cessation
Brief Summary: In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.


Options:
A: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: APD356 10 mg b.i.d.; Type: EXPERIMENTAL; Interventions: Drug: APD356-lorcaserin hydrochloride | Arm Label: APD356 10 mg q.d.; Type: EXPERIMENTAL; Interventions: Drug: APD356-lorcaserin hydrochloride | Arm Label: Placebo 10 mg b.i.d; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: APD356-lorcaserin hydrochloride; Assigned to Arm(s): APD356 10 mg b.i.d., APD356 10 mg q.d. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 10 mg b.i.d
D: Arm Label: Electronic cigarette condition; Type: EXPERIMENTAL; Interventions: Drug: Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline | Arm Label: Varenicline condition; Type: ACTIVE_COMPARATOR; Interventions: Drug: Electronic cigarette without nicotine (ECwN) plus active varenicline tablets | Arm Label: Placebo condition; Type: PLACEBO_COMPARATOR; Interventions: Drug: Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline | Intervention Type: DRUG; Name: Electronic cigarette without nicotine (ECwN) plus active varenicline tablets; Assigned to Arm(s): Varenicline condition | Intervention Type: DRUG; Name: Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline; Assigned to Arm(s): Placebo condition | Intervention Type: DRUG; Name: Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline; Assigned to Arm(s): Electronic cigarette condition

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pulmonary Rehabilitation in Fibrotic Pulmonary Sarcoidosis (Stage IV): Randomized Controlled Trial
Brief Summary: The primary objective of the study is to assess the improvement of daily activity in subjects with Stage IV Pulmonary Sarcoidosis one year after the conduct of a pulmonary rehabilitation program.

The secondary objectives are the following:

* assess the improvement of daily activity at several times : 2, 6 and 12 months after the beginning of a pulmonary rehabilitation program
* assess the improvement of exercise capacity by tests used in medical practice
* assess the correlation between daily activity and exercise capacity
* assess the improvement of dyspnea
* assess the improvement of quality of life and psychological state


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Pulmonary Rehabilitation | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): 1
C: Arm Label: Pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Pulmonary rehabilitation program | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pulmonary rehabilitation program; Assigned to Arm(s): Pulmonary rehabilitation
D: Arm Label: Nintedanib; Type: EXPERIMENTAL; Interventions: Drug: Nintedanib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nintedanib; Assigned to Arm(s): Nintedanib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pragmatic Randomized Trial to Investigate the Effectiveness of BehaviouRal ActiVation Group Therapy in Reducing dEpressive Symptoms and Improving Quality of Life in Patients With Depression: BRAVE Pilot Study
Brief Summary: The study's primary goal is to assess the effectiveness of behavioural activation in reducing depressive symptoms and re-integrate patients with depression into their personal and professional lives thus improving quality of life and helping in attaining and maintaining remission of depression. It is aimed at helping patients re-engage with several life areas that they may have lost in the course of depressive illness. The intervention is centred on behavioural activation (BA) with complementary interventions including recreation activities, and behavioural modifications. The study question is: in patients with depressive disorder attending a specialized hospital based mood disorders clinic, does the addition of behavioural activation program delivered in a group format improve depressive symptoms and quality of life compared to treatment as usual after 18 weeks of treatment? Study investigators hypothesize that behavioural activation is an effective treatment for depressive disorder in patients with depression.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: REJOICE | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: REJOICE; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral activation psychotherapy | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: Behavioral activation psychotherapy; Assigned to Arm(s): Behavioral Activation | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual Care
C: Arm Label: Support Group (Control Group); Type: OTHER; Interventions: Behavioral: Support Group | Arm Label: Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Behavioral Activation | Intervention Type: BEHAVIORAL; Name: Support Group; Assigned to Arm(s): Support Group (Control Group)
D: Arm Label: Behavioral Activation Treatment for Depression; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for Depression Treatment | Arm Label: Supportive Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Counseling | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for Depression Treatment; Assigned to Arm(s): Behavioral Activation Treatment for Depression | Intervention Type: BEHAVIORAL; Name: Supportive Counseling; Assigned to Arm(s): Supportive Counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Surgical Pleth Index - Relevance in Small Children. A Randomised Double Blinded Study
Brief Summary: Surgical Pleth index is a novel device aimed for measurement of intraoperative nosiseption. It has not been tested on small children. The aim of this study is to measure, whether there is a difference in nosiception measured by SPI in a group receiving local anesthetics prior to operation compared to group receiving plasebo.


Options:
A: Arm Label: Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levobupivacaine, Drug: Saline | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Levobupivacaine, Drug: Saline | Intervention Type: DRUG; Name: Levobupivacaine; Assigned to Arm(s): Control group, Treatment | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Control group, Treatment
B: Arm Label: Quadratus Lumborum Block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Quadratus Lumborum Block | Arm Label: Transversus abdominis plane block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transversus Abdominis Plane Block | Intervention Type: PROCEDURE; Name: Quadratus Lumborum Block; Assigned to Arm(s): Quadratus Lumborum Block | Intervention Type: PROCEDURE; Name: Transversus Abdominis Plane Block; Assigned to Arm(s): Transversus abdominis plane block
C: Arm Label: Transversus Abdominis Plane Block; Type: EXPERIMENTAL; Interventions: Procedure: Transversus Abdominis Plane Block | Arm Label: Caudal Epidural Block; Type: EXPERIMENTAL; Interventions: Procedure: Caudal Epidural | Intervention Type: PROCEDURE; Name: Caudal Epidural; Assigned to Arm(s): Caudal Epidural Block | Intervention Type: PROCEDURE; Name: Transversus Abdominis Plane Block; Assigned to Arm(s): Transversus Abdominis Plane Block
D: Arm Label: Regional block; Type: EXPERIMENTAL; Interventions: Procedure: bilateral ultrasound-guided rectus sheath block | Arm Label: Wound infiltration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wound infiltration | Intervention Type: PROCEDURE; Name: bilateral ultrasound-guided rectus sheath block; Assigned to Arm(s): Regional block | Intervention Type: PROCEDURE; Name: Wound infiltration; Assigned to Arm(s): Wound infiltration

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Brief Summary: The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.


Options:
A: Arm Label: Single Dose of Zostavax; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 1; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 3; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Single Dose of Zostavax, Zostavax - Day 0 and Month 1, Zostavax - Day 0 and Month 3
B: Arm Label: GSK1437173A Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Boostrix | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Boostrix | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK 1437173A; Assigned to Arm(s): Control Group, GSK1437173A Group | Intervention Type: BIOLOGICAL; Name: Boostrix; Assigned to Arm(s): Control Group, GSK1437173A Group
C: Arm Label: Co-Ad Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK 1437173A; Assigned to Arm(s): Co-Ad Group, Control Group | Intervention Type: BIOLOGICAL; Name: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™; Assigned to Arm(s): Co-Ad Group, Control Group
D: Arm Label: NBP608; Type: EXPERIMENTAL; Interventions: Biological: NBP608 | Arm Label: Zostavax; Type: ACTIVE_COMPARATOR; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: NBP608; Assigned to Arm(s): NBP608 | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Zostavax

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Brief Summary: The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.


Options:
A: Arm Label: Single Dose of Zostavax; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 1; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 3; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Single Dose of Zostavax, Zostavax - Day 0 and Month 1, Zostavax - Day 0 and Month 3
B: Arm Label: GSK1437173A formulation 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: GSK1437173A formulation 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: GSK1437173A formulation 3 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes zoster vaccine GSK1437173A; Assigned to Arm(s): GSK1437173A formulation 1 Group, GSK1437173A formulation 2 Group, GSK1437173A formulation 3 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Control Group
C: Arm Label: Zoster vaccine group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster Vaccine GSK1437173A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes Zoster Vaccine GSK1437173A; Assigned to Arm(s): Zoster vaccine group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: Co-Ad Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK 1437173A; Assigned to Arm(s): Co-Ad Group, Control Group | Intervention Type: BIOLOGICAL; Name: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™; Assigned to Arm(s): Co-Ad Group, Control Group

Answer: D